![Third COVID-19 dose approved by EMA 28 days after second vaccination - Hospital Pharmacy EuropeHospital Pharmacy Europe Third COVID-19 dose approved by EMA 28 days after second vaccination - Hospital Pharmacy EuropeHospital Pharmacy Europe](https://hospitalpharmacyeurope.com/wp-content/uploads/2021/08/HPE-GettyImages-1281635877-second-covid-dose.jpg)
Third COVID-19 dose approved by EMA 28 days after second vaccination - Hospital Pharmacy EuropeHospital Pharmacy Europe
European Commission - Vaccinate, vaccinate and boost! Evidence gathered by the European Medicines Agency and the European Centre for Disease Prevention and Control (ECDC) suggest that mRNA vaccines used as boosters 3
![News - The European Commission and the Committee for Medicinal Products for Human Use at the EMA Voted Positively for mRNA Booster Vaccinations from BioNTech/Pfizer and Moderna Adapted to the Omicron Virus News - The European Commission and the Committee for Medicinal Products for Human Use at the EMA Voted Positively for mRNA Booster Vaccinations from BioNTech/Pfizer and Moderna Adapted to the Omicron Virus](https://www.pei.de/SharedDocs/Bilder/EN/newsroom-en/hp-news-pm/omicron-ba1-chmp.jpg?__blob=thumbnail&v=4)
News - The European Commission and the Committee for Medicinal Products for Human Use at the EMA Voted Positively for mRNA Booster Vaccinations from BioNTech/Pfizer and Moderna Adapted to the Omicron Virus
Brianda Echevarria on LinkedIn: EMA evaluating data on booster dose of COVID-19 Vaccine Janssen - European…
Repeat booster shots have immune-system risks: European Medicines Agency | World News - Hindustan Times
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines | CDE Almería - Centro de Documentación Europea - Universidad de Almería ECDC-EMA statement on booster vaccination with Omicron adapted bivalent COVID-19 vaccines | CDE Almería - Centro de Documentación Europea - Universidad de Almería](https://www.cde.ual.es/wp-content/uploads/2022/05/vacunas.jpg)